CAPLIN POINT share price has plunged 7% and is presently trading at Rs 1,475.1.
Meanwhile, the BSE HEALTHCARE index is at 40,926.1 (up 0.2%).
Among the top losers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (down 7.5%) and FDC (down 3.7%).
ALKEM LABORATORIES (up 3.6%) and ERIS LIFESCIENCES (up 3.3%) are among the top gainers today.
Over the last one year, CAPLIN POINT has moved up from Rs 896.5 to Rs 1,475.1, registering a gain of Rs 578.7 (up 64.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 40,926.1, registering a gain of 44.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 115.2%), GSK Pharma (up 105.8%) and SUVEN PHARMACEUTICALS (up 104.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 78,886.2 (down 0.7%).
The top losers among the BSE Sensex today are Asian Paints (down 3.6%) and Infosys (down 2.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,098.7 (down 0.8%). LTIMINDTREE and Grasim Industries are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 78,886.2, registering a gain of 12,932.7 points (up 19.6%).
CAPLIN POINT net profit grew 19.9% YoY to Rs 1,249 million for the quarter ended June 2024, compared to a profit of Rs 1,042 million a year ago. Net sales rose 16.1% to Rs 4,590 million during the period as against Rs 3,953 million in April-June 2023.
For the year ended March 2023, CAPLIN POINT reported 22.2% increase in net profit to Rs 3,770 million compared to net profit of Rs 3,085 million during FY22. Revenue of the company grew 15.5% to Rs 14,667 million during FY23.
The current Price to earnings ratio of CAPLIN POINT, based on rolling 12 month earnings, stands at 23.3.
Equitymaster requests your view! Post a comment on "CAPLIN POINT Plunges 7%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!